Side-by-side research comparison of Retatrutide and Tirzepatide across our PubMed, ClinicalTrials.gov, and EuropePMC corpus. No direct head-to-head trials in our corpus — this comparison synthesizes indirect evidence across 67 Retatrutide studies and 424 Tirzepatide studies.
| Retatrutide | Tirzepatide | |
|---|---|---|
| Drug class | glp 1 agonist, gip agonist, glucagon agonist | glp 1 agonist, gip agonist |
| Studies in corpus | 67 | 424 |
| Highest evidence tier | meta analysis | rct |
| Evidence tier mix | review · 16 preclinical animal · 3 other · 11 rct · 16 meta analysis · 4 | other · 3 cohort · 1 rct · 3 review · 2 case report · 1 |
| Studies with explicit sample size | 2 | 4 |
| Head-to-head studies in corpus | 0 — indirect comparison only | |
Beyond the literature: here's what third-party Certificate-of-Analysis records (Janoshik, BCC, Auxlabs) say about real Retatrutide and Tirzepatide batches we've tested. Aggregate, public data — cross-reference against the studies below.
We tested 20064 Retatrutide batches across 2698 manufacturers, 99.66% avg purity.
We tested 12739 Tirzepatide batches across 1778 manufacturers, 99.68% avg purity.
We hold deeper lab coverage on Retatrutide (20064 batches tested). Tirzepatide edges ahead on average measured purity (99.66% vs 99.68%) — a narrow gap; weigh it against failed-batch and underdose counts above.
Looking for vendor-level purity, endotoxin, and HPLC data on Retatrutide or Tirzepatide? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.